Underwriting Agreement
Exhibit 1.1
VOLCANO CORPORATION
1.75% Convertible Senior Notes due 2017
Underwriting Agreement
December 4, 2012
J.P. Morgan Securities LLC
Goldman, Sachs & Co.
as
Representatives of the
several Underwriters
listed in Schedule 1 hereof
c/o J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
c/o Goldman, Sachs & Co.
200 West Street
New York, NY 10282
Ladies and Gentlemen:
Volcano
Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to J.P. Morgan Securities LLC and Goldman, Sachs & Co. and each of the other underwriters, if any, named on Schedule 1 hereto (each an
“Underwriter” and collectively, the “Underwriters”), for whom J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as representatives (the “Representatives”), $400,000,000 principal amount of its
1.75% Convertible Senior Notes due 2017 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $60,000,000 principal amount of its 1.75% Convertible Senior Notes due 2017 (the “Option
Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 1.75% Convertible Senior Notes due 2017 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and,
if and to the extent issued, the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.001 per
share (the “Common Stock”). The Securities will be issued pursuant to an Indenture dated as of September 20, 2010 (the “Base Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the
“Trustee”), as supplemented by a supplemental indenture, to be dated as of December 10, 2012 (the “Supplemental Indenture”, and, together with the Base Indenture, the “Indenture”), between the Company and the
Trustee. The Common Stock will have attached thereto rights (the “Rights”) to purchase Series A Junior Participating Preferred Stock, par value $0.001. The Rights are to be issued pursuant to a Rights Agreement (the “Rights
Agreement”) dated as of June 20, 2006 between the Company and American Stock Transfer & Trust Company.
The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Securities, as follows:
1. Registration Statement. The Company has prepared and filed with the
Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities Act”), a registration statement (File
No. 333-169341) including a prospectus, relating to the Securities, the Underlying Securities and Rights. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A,
430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (“Rule 430 Information”), is referred to herein as the “Registration Statement”; and as used herein, the term
“Preliminary Prospectus” means any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430
Information, and the term “Prospectus” means the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities. Any
reference in this Agreement to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities
Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be and any reference to “amend”, “amendment” or “supplement” with respect to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder (collectively, the “Exchange Act”) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the
Prospectus.
At or prior to the time when sales of the Securities were first made (the “Time of Sale”), the Company
had prepared the following information (collectively, the “Time of Sale Information”): the Preliminary Prospectus dated December 3, 2012, and each “free-writing prospectus” (as defined pursuant to Rule 405 under the
Securities Act) listed on Annex A hereto.
2. Purchase of the Securities by the Underwriters.
(a) The Company agrees to issue and sell the Underwritten Securities to the several Underwriters as provided in this Agreement, and each
Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from the Company the respective principal amount of
Underwritten Securities set forth opposite such Underwriter’s name in Schedule 1 hereto at a price equal to 97% of the principal amount thereof (the “Purchase Price”) plus accrued interest, if any, from December 4, 2012 to the
Closing Date (as defined below).
In addition, the Company agrees to issue and sell the Option Securities to the several
Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth
Page 2
herein, shall have the option to purchase, severally and not jointly, from the Company the Option Securities at the Purchase Price plus accrued interest, if any, from the Closing Date to the date
of payment and delivery. The option granted hereunder is for use by the Underwriters solely in covering any over-allotments in connection with the initial offering of the Underwritten Securities by the Underwriters.
If any Option Securities are to be purchased, the amount of Option Securities to be purchased by each Underwriter shall be the amount of
Option Securities which bears the same ratio to the aggregate amount of Option Securities being purchased as the amount of Underwritten Securities set forth opposite the name of such Underwriters in Schedule 1 hereto (or such amount increased as set
forth in Section 10 hereof) bears to the aggregate amount of Underwritten Securities being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate Option Securities in denominations other than
$1,000 as the Representatives in their sole discretion shall make.
The Underwriters may exercise the option to purchase the
Option Securities at any time in whole, or from time to time in part, by written notice from the Representatives to the Company; provided that any such notice shall specify an Additional Closing Date (as hereafter defined) to occur on a date
no later than the last day in the 13-day period commencing on and including the Closing Date (as hereinafter defined), following which date the option shall expire. Such notice shall set forth the aggregate amount of Option Securities as to which
the option is being exercised and the date and time when the Option Securities are to be delivered and paid for which may be the same date and time as the Closing Date but shall not be earlier than the Closing Date or, with respect to any Option
Securities to be delivered after the Closing Date, no earlier than two (2) business days after the date of such notice and in any event no later than the last day in the 13-day period commencing on and including the Closing Date unless the
Representatives and the Company otherwise agree in writing (unless such time and date are postponed in accordance with the provisions of Section 10 hereof, provided that with respect to the Additional Closing Date, in no event shall the
Additional Closing Date be postponed to a date later than the last day in the 13-day period commencing on and including the Closing Date).
(b) The Company understands that the Underwriters intend to make a public offering of the Securities as soon after the effectiveness of this Agreement as in the judgment of the Representatives is
advisable, and initially to offer the Securities on the terms set forth in the Prospectus. The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate of an Underwriter, and that any such
affiliate may offer and sell Securities purchased by it to or through any Underwriters; provided that such offers and sales shall be made in accordance with the provisions of this Agreement.
(c) Payment for the Securities shall be made by wire transfer in immediately available funds to the account specified by the Company to
the Representatives in the case of the Underwritten Securities, at the offices of J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 at 10:00 A.M. New York City time on December 10, 2012, or at such other time or place on
the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Securities, on the date and at the time and place specified by the
Representatives in the written notice of the Underwriters’ election to purchase such Option Securities. The time and
Page 3
date of such payment for the Underwritten Securities is referred to herein as the “Closing Date” and the time and date for such payment for the Option Securities, if other than the
Closing Date, is herein referred to as the “Additional Closing Date”.
Payment for the Securities to be purchased on
the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the nominee of The Depositary Trust Company (“DTC”), for the respective accounts of the several Underwriters of the Securities to be
purchased on such date of one or more global notes representing the Securities (collectively, the “Global Note”), with any transfer taxes payable in connection with the sale of such Securities duly paid by the Company. The Global Note will
be made available for inspection by the Representatives at the office of J.P. Morgan Securities LLC set forth above not later than 1:00 P.M., New York City time, on the business day prior to the Closing Date or the Additional Closing Date, as the
case may be.
(d) The Company acknowledges and agrees that the Underwriters are acting solely in the capacity of an arm’s
length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the
Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall
consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability to the
Company with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf
of the Company.
3. Representations and Warranties of the Company. The Company represents and warrants to each
Underwriter that:
(a) Preliminary Prospectus. No order preventing or suspending the use of any Preliminary Prospectus
has been issued by the Commission, and the Preliminary Prospectus included in the Time of Sale Information, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of
filing thereof, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in
writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section 7(b) hereof.
(b) Time of Sale Information. The Time of Sale Information, at the Time of Sale, did not,
and at the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact required to be
Page 4
stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no
representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use in such Time of Sale Information, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof. No statement of material fact
included in the Prospectus has been omitted from the Time of Sale Information and no statement of material fact included in the Time of Sale Information that is required to be included in the Prospectus has been omitted therefrom.
(c) Issuer Free Writing Prospectus. Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the
Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not made, used, prepared, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any
“written communication” (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its agents and representatives (other
than a communication referred to in clause (i) below, an “Issuer Free Writing Prospectus”) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the
Securities Act or (ii) the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complied in all
material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and, when taken together with the Preliminary Prospectus
filed, accompanying or delivered prior to delivery of such Issuer Free Writing Prospectus, did not, and at the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any
statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly
for use in such Issuer Free Writing Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof. Each such Issuer Free Writing
Prospectus, as of its issue date and at all subsequent times through the completion of the initial offering and sale of the Securities by the Underwriters or until any earlier date that the Company notified or notifies the Representatives as
described in Section 4(e), did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by
reference therein and any Preliminary Prospectus deemed to be a part thereof that has not been superseded or modified.
(d)
Registration Statement and Prospectus. The Registration Statement is an “automatic shelf registration statement” as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years
prior to the date hereof; and no
Page 5
notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by
the Company. No order suspending the effectiveness of the Registration Statement has been issued by the Commission and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering
has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement complied and will comply in
all material respects with the Securities Act and the Trust Indenture Act of 1939, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Trust Indenture Act”), and did not and will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and
as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus does not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to (i) that part of the Registration
Statement that constitutes the Statement of Eligibility and Qualification (Form T-1) of the Trustee under the Trust Indenture Act or (ii) any statements or omissions made in reliance upon and in conformity with information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only
such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.
(e)
Incorporated Documents. The documents incorporated by reference in the Registration Statement, the Prospectus or the Time of Sale Information, when they became effective or were filed with the Commission, as the case may be, conformed in all
material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Time of
Sale Information, when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
(f) Financial Statements. The financial statements and the related notes thereto of the Company and its consolidated subsidiaries
included or incorporated by reference in the Registration Statement, the Time of Sale Information and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and
present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such
financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on
Page 6
a consistent basis throughout the periods covered thereby; and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects
the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Time of Sale Information and the Prospectus has been derived from the accounting records of
the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby.
(g)
No Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Time of Sale Information and the Prospectus, (i) there has not
been any material change in the capital stock, long-term debt, or current portion of long-term debt of the Company or any of its consolidated subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by
the Company on any class of capital stock, or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, management, financial position, stockholders’ equity or
results of operations of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as a whole
or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any material loss or interference with
its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in
the case of each of (i), (ii) and (iii) as otherwise disclosed in the Registration Statement, the Time of Sale Information and the Prospectus.
(h) Organization and Good Standing. The Company and each of its subsidiaries have been duly organized or formed, as applicable, and are validly existing and in good standing (where such concept is
recognized under the laws of the jurisdiction in which they are organized or formed) under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing (where such concept is recognized under
the laws of the applicable jurisdiction) in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or
hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing, as applicable, or have such power or authority would not, individually or in the aggregate,
have a material adverse effect on the business, properties, management, financial position, stockholders’ equity or results of operations of the Company and its subsidiaries taken as a whole or on the performance by the Company of its
obligations under the Transaction Documents (as defined below) (a “Material Adverse Effect”). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in
Schedule 2 to this Agreement.
(i) Capitalization. The Company has an authorized equity capitalization as set forth in
the Registration Statement, the Time of Sale Information and the Prospectus under the heading “Description of Capital Stock”; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and
are fully paid and non-assessable and are not subject to any pre-emptive or similar rights granted by the Company or provided for under applicable law or the Company’s certificate of incorporation or bylaws; except as described in or
Page 7
expressly contemplated by the Time of Sale Information and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or
instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the
issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description
thereof contained in the Registration Statement, the Time of Sale Information and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been
duly and validly authorized and issued, are (to the extent such concept is applicable to the equity interest owned) fully paid and non-assessable, and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance,
security interest, restriction on voting or transfer or any other claim of any third party.
(j) Stock Options. With
respect to the stock options (the “Stock Options”) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the “Company Stock Plans”), (i) each Stock Option intended to qualify as an
“incentive stock option” under Section 422 of the Code so qualifies, and (ii) since June 19, 2006 (the “Initial Trading Date”): (a) each grant of a Stock Option was duly authorized no later than the date on
which the grant of such Stock Option was by its terms to be effective (the “Grant Date”) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized
committee thereof) and any required stockholder approval by the necessary number of votes or written consents, (b) each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws
and regulatory rules or requirements, including the rules of the Nasdaq Global Select Market and any other exchange on which Company securities are traded, (c) the per share exercise price of each Stock Option was not less than the fair market
value of a share of Common Stock on the applicable Grant Date (as determined in accordance with the terms of the Company Stock Plans) and (d) each such grant was properly accounted for in accordance with GAAP in the financial statements
(including the related notes) of the Company and disclosed in the Company’s filings with the Commission in accordance with the Exchange Act and all other applicable laws. Since the Initial Trading Date, the Company has not knowingly granted,
and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinate the grant of Stock Options with, the release or other public announcement of material information regarding the Company or
its subsidiaries or their results of operations or prospects.
(k) Due Authorization. The Company has all requisite
corporate power and authority to execute and deliver this Agreement, the Indenture and the Securities (collectively, the “Transaction Documents”) and to perform its obligations hereunder and thereunder; and all action required to be taken
for the due and proper authorization, execution and delivery by it of each of the Transaction Documents and the consummation by it of the transactions contemplated thereby or by the Time of Sale Information and the Prospectus has been duly and
validly taken.
(l) The Indenture. The Base Indenture has been duly authorized by the Company and duly qualified under
the Trust Indenture Act and, assuming the due authorization, execution and delivery in accordance with its terms by each of the other parties thereto, constitutes a valid and legally binding agreement of the Company enforceable against the Company
in accordance with its
Page 8
terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights generally or by equitable principles relating to
enforceability (collectively, the “Enforceability Exceptions”). The Supplemental Indenture has been duly authorized by the Company and, when duly authorized, executed and delivered in accordance with its terms by each of the other parties
thereto, the Indenture will constitute a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by the Enforceability Exceptions.
(m) Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.
(n) The Securities. The Securities to be issued and sold by the Company hereunder have been duly authorized by the Company and,
when duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company
enforceable against the Company in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture.
(o) The Underlying Securities. Upon issuance and delivery of the Securities in accordance with this Agreement and the Indenture, the Securities will be convertible at the option of the holder
thereof into shares of the Underlying Securities in accordance the terms of the Securities; the Underlying Securities reserved for issuance upon conversion of the Securities have been duly authorized and reserved and, when issued upon conversion of
the Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non assessable, and the issuance of the Underlying Securities will not be subject to any preemptive or similar rights granted by the Company or
provided for under applicable law or the Company’s certificate of incorporation or bylaws; the Rights Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and legally binding agreement of the Company
enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions; and the Rights have been duly authorized by the Company and, when issued upon issuance of the Underlying Securities, will be validly issued, and
the Series A Junior Participating Preferred Stock of the Company has been duly authorized by the Company and validly reserved for issuance and, upon the exercise of the Rights in accordance with the terms of the Rights Agreement, will be validly
issued, fully paid and non-assessable.
(p) Descriptions of the Transaction Documents. Each Transaction Document
conforms in all material respects to the description thereof contained in the Registration Statement, the Time of Sale Information and the Prospectus.
(q) No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no
event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or
(iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
Page 9
or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of clauses (ii) and (iii) above,
for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.
(r) No
Conflicts. The execution, delivery and performance by the Company of each of the Transaction Documents, the issuance and sale of the Securities (including the issuance of the Underlying Securities upon conversion thereof) and the consummation of
the transactions contemplated by the Transaction Documents or the Time of Sale Information and the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or
result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to
which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii) result in any violation of
the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default
that would not, individually or in the aggregate, have a Material Adverse Effect.
(s) No Consents Required. No
consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of each of the Transaction
Documents, the issuance and sale of the Securities (including the issuance of the Underlying Securities upon conversion thereof) and the consummation of the transactions contemplated by the Transaction Documents or the Time of Sale Information and
the Prospectus, except for the registration of the Securities under the Securities Act, the qualification of the Indenture under the Trust Indenture Act and for such consents, approvals, authorizations, orders and registrations or qualifications as
have been obtained, copies of which have been provided to the Representatives, or as may be required under applicable state securities laws in connection with the purchase and resale of the Securities by the Underwriters.
(t) Legal Proceedings. Except as described in the Registration Statement, the Time of Sale Information and the Prospectus, there
are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is a party or to which any property of the Company or any of its subsidiaries is or may be the subject
that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; no such investigations, actions, suits or proceedings are threatened or to the
best knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending legal, governmental or regulatory actions, suits or proceedings that are required under the
Securities Act to be described in the Registration Statement or the Prospectus that are not so described in the Registration Statement, the Time of Sale Information and the Prospectus and (ii) there are no statutes, regulations or contracts or
Page 10
other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Time of Sale Information or the
Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Time of Sale Information and the Prospectus.
(u) Independent Accountants. KPMG LLP, which has certified certain financial statements of the Company and its consolidated subsidiaries, is an independent registered public accounting firm with
respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Exchange Act and (ii) Ernst &
Young LLP, which has certified certain financial statements of the Company and its consolidated subsidiaries, was as of the date of its report incorporated by reference in the Time of Sale Information and the Prospectus an independent registered
public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Exchange Act.
(v) Title to Real and Personal Property. The Company and its subsidiaries have good and marketable title to, or have
valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and
imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect.
(w) Title to Intellectual Property. The Company owns, possesses or can
acquire on commercially reasonable terms rights to use all Intellectual Property (as defined below) necessary for the conduct of the business of the Company as described in the Time of Sale Information and the Prospectus as now conducted, and,
except as disclosed in the Time of Sale Information and the Prospectus: (i) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property, except as such as would not
reasonably be expected to have a Material Adverse Effect; (ii) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual
Property, except as such as would not have a Material Adverse Effect and the Company is unaware of any facts which would form a reasonable basis for any such claim; (iii) the Intellectual Property owned by the Company and, to the knowledge of
the Company, the Intellectual Property licensed to the Company have not been adjudged invalid or unenforceable, in whole or in part, and, except as such as would not reasonably be expected to have a Material Adverse Effect, there is no pending or,
to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such
claim; (iv) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights
of others in any material respect, and the Company has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim; and (v) to the Company’s knowledge,
no employee of the Company is in or has ever been in violation of any term of any
Page 11
employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or
with a former employer where the basis of such violation relates to such employee’s employment with the Company, or actions undertaken by the employee while employed with the Company, except for any such violation which would not have a
Material Adverse Effect. The term “Intellectual Property” as used herein means all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets,
technology, know-how and other intellectual property.
(x) No Undisclosed Relationships. No relationship, direct or
indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities
Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Time of Sale Information.
(y) Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Registration
Statement, the Time of Sale Information and the Prospectus, will not be required to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company
Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”).
(z) Taxes. The Company and its subsidiaries have paid all material federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof; and except
as otherwise disclosed in the Registration Statement, the Time of Sale Information and the Prospectus, there is no material tax deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries
or any of their respective properties or assets.
(aa) Licenses and Permits. The Company has all necessary consents,
authorizations, approvals, orders, certificates and permits of and from (collectively, the “Governmental Permits”), and has made all declarations and filings with, all federal, state, local and other governmental authorities, all
self-regulatory organizations and all courts and other tribunals, to own, lease, license and use its properties and assets and to conduct its business in the manner described in the Registration Statement, the Time of Sale Information and the
Prospectus, except to the extent that the failure to obtain or file the same would not have a Material Adverse Effect; and the Company has not received any notice of proceedings relating to the revocation or modification of any such Governmental
Permits which, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.
(bb)
No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the best knowledge of the Company, is contemplated or threatened and the Company is not aware of any existing or
imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, except as would not have a Material Adverse Effect.
Page 12
(cc) Compliance With Environmental Laws. (i) The Company and its subsidiaries
(x) are, and at all prior times were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions and orders relating to the protection of human health or safety, the
environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”), (y) have received and are in compliance with all permits, licenses, certificates or other
authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, and (z) have not received notice of any actual or potential liability under or relating to any Environmental Laws,
including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such
notice, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such failure to comply, or failure to
receive required permits, licenses or approvals, or cost or liability, as would not, individually or in the aggregate, have a Material Adverse Effect; and (iii) except as described in each of the Registration Statement, the Time of Sale
Information and the Prospectus, (y) there are no proceedings that are pending, or that are known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is
also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, the Company and its subsidiaries are not aware of any issues regarding compliance with Environmental Laws,
or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a material adverse effect on the capital expenditures, earnings
or competitive position of the Company and its subsidiaries taken as a whole; and (z) none of the Company and its subsidiaries anticipates material capital expenditures relating to Environmental Laws. In the ordinary course of business, the
Company conducts periodic reviews of the effect of the Environmental Laws on the respective businesses, operations and properties of the Company and its subsidiaries, in the course of which the Company identifies and evaluates material associated
costs and liabilities (including, without limitation, any capital or operating expenditures required for cleanup, closure of properties or compliance with the Environmental Laws or any permit, license or approval, any related constraints on
operating activities and any potential liabilities to third parties).
(dd) Hazardous Substances. There has been no
storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic wastes or hazardous substances, including, but not limited to, any naturally occurring radioactive materials, brine,
drilling mud, crude oil, natural gas liquids and other petroleum materials, by, due to or caused by the Company or any of its subsidiaries (or, to the Company’s knowledge, any other entity (including any predecessor) for whose acts or omissions
the Company or any of its subsidiaries is or would reasonably be expected to be liable) upon any of the property now or previously owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any
Environmental Laws or in a manner or to a location that would reasonably be expected to give rise to any liability under the Environmental Laws, except for any violation or liability which would not, individually or in the aggregate, have a Material
Adverse Effect.
Page 13
(ee) Compliance With ERISA. (i) Each employee benefit plan, within the meaning
of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any organization which is a member of a controlled group
of corporations within the meaning of Section 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended (the “Code”)) has any liability (each, a “Plan”) has been maintained in all material respects
in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or
Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code
or Section 302 of ERISA, no failure to satisfy the minimum funding standard of Section 412 of the Code or Section 302 of ERISA, whether or not waived, has occurred or is reasonably expected to occur; (iv) with respect to each
Plan that is subject to Title IV of ERISA, the fair market value of the assets of each Plan are at least equal in value to the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan);
(v) no “reportable event” (within the meaning of Section 4043(c) of ERISA) that would result in material liability to the Company or any member of its Controlled Group has occurred or is reasonably expected to occur with respect
to any Plan; and (vi) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary
course and without default) in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(a)(3) of ERISA).
(ff) Disclosure Controls. The Company maintains an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is designed to ensure
that information required to be disclosed by the Company and its subsidiaries in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules
and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried
out evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.
(gg) Accounting Controls. The Company maintains a system of “internal control over financial reporting” (as defined in
Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and have been designed by, or under the supervision of, the Company’s principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
Registration Statement fairly presents the information
Page 14
called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Time
of Sale Information and the Prospectus, there are no material weaknesses in the Company’s internal controls. The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all
significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial
information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.
(hh) eXtensible Business Reporting Language. The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.
(ii) Insurance. The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and
businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are reasonable and customary in the Company’s industry to protect the Company and its subsidiaries and their
respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that any material capital improvements or other material expenditures are required or necessary to be
made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary
to continue its business.
(jj) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor, to the best
knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision
of the Foreign Corrupt Practices Act of 1977; or (iv) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment.
(kk) Compliance with Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and
reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the
Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(ll) Compliance with OFAC. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or
Page 15
any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”); and the Company
will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.
(mm) No Restrictions
on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other
distribution on such subsidiary’s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other
subsidiary of the Company.
(nn) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to
any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder’s fee or like
payment in connection with the offering and sale of the Securities.
(oo) No Stabilization. The Company has not taken,
directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities.
(pp) Margin Rules. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described in the Registration Statement, the Time of Sale
Information and the Prospectus will result in a violation by the Company of Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.
(qq) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Information and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(rr) Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe
that the statistical and market-related data included in the Registration Statement, the Time of Sale Information and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.
(ss) Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), including
Section 402 related to loans and Sections 302 and 906 related to certifications.
Page 16
(tt) Status under the Securities Act. At the time of filing the Registration
Statement and any post-effective amendments thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and at
the date hereof, the Company was not and is not an “ineligible issuer,” and is a well-known seasoned issuer, in each case as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant
to Rule 456(b)(1) under the Securities Act or will pay such fees within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date.
(uu) No Ratings. There are no securities or preferred stock of or guaranteed by the Company or any of its subsidiaries that are
rated by a “nationally recognized statistical rating organization,” as such term is defined by the Commission for purposes of Rule 436(g)(2) under the Securities Act.
(vv) Regulatory Compliance. Except as described in the Registration, the Time of Sale Information and the Prospectus, the Company:
(i) within the last five (5) years has not received any Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration or any other court or arbitrator or
federal, state, local or foreign governmental or regulatory authority (each, a “Governmental Authority”) alleging or asserting noncompliance with any health care laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such health care laws (“Authorizations”), except in each case as would not, individually or in the aggregate, have a Material Adverse Effect; (ii) possesses all
Authorizations and such Authorizations are valid and in full force and effect and the Company is not in violation in any material respect of any term of any such Authorizations; (iii) has not received notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product operation or activity is in violation of any health care laws or Authorizations and has no
knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, except in each case as would not, individually or in the aggregate, have a Material
Adverse Effect; (iv) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is
considering such action; (v) (a) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any health care laws or
Authorizations, (b) except as would not, individually or in the aggregate, have a Material Adverse Effect, all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and
correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission), and (c) the Company is not aware of any reasonable basis for any material liability with respect to such filings; (vi) has not,
either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, “dear doctor” letter, or other notice or
action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action,
except in each case as would not, individually or in the aggregate, have a Material Adverse Effect; and (vii) has not, and to the knowledge of the Company, the
Page 17
Company’s officers, employees and agents have not, made any untrue statement of a material fact or fraudulent statement to any Governmental Authority or failed to disclose a material fact
required to be disclosed to any Governmental Authority.
(ww) Suppliers. No supplier of merchandise to the Company has
ceased shipments of merchandise to the Company, which cessation would result in a Material Adverse Effect.
(xx) Studies,
Tests and Trials. To the Company’s knowledge, the descriptions of and information regarding the studies, tests and trials, and the data and results derived therefrom, contained in the Registration Statement, the Time of Sale Information and
the Prospectus are accurate and complete in all material respects and the Company, after due inquiry, is not aware of any other studies, tests, trials, presentations, publications or other information relating to the Company’s products that are
not described in the Registration Statement, the Time of Sale Information and the Prospectus and that would reasonably call into question the validity, completeness, or accuracy of any study, test, trial, results or data described in the
Registration Statement, the Time of Sale Information and the Prospectus when viewed in the context in which such studies, tests, trials results, or data are described therein.
4. Further Agreements of the Company. The Company covenants and agrees with each Underwriter that:
(a) Required Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file
any Issuer Free Writing Prospectus (including the term sheet substantially in the form of Annex B hereto) to the extent required by Rule 433 under the Securities Act; and will file promptly all reports and any definitive proxy or information
statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in
connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus (to the extent not previously delivered) to the Underwriters in New York City as promptly as practicable following the date hereof and in
any event not later than the second business day following the date hereof in such quantities as the Representatives may reasonably request, and will furnish each Issuer Free Writing Prospectus (to the extent not previously delivered) to the
Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. The Company will pay the registration fees for
this offering within the time period required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date.
(b) Delivery of Copies. Upon the request of the Representatives, the Company will deliver, without charge, (i) to the
Representatives, one photocopy of the signed copy of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii) to each Underwriter (A) a conformed
copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements
thereto and documents incorporated by reference
Page 18
therein) and each Issuer Free Writing Prospectus as the Representatives may reasonably request. As used herein, the term “Prospectus Delivery Period” means such period of time after the
first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act)
in connection with sales of the Securities by any Underwriter or dealer.
(c) Amendments or Supplements, Issuer Free
Writing Prospectuses. Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or the Prospectus, whether
before or after the time that the Registration Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of such proposed Issuer Free Writing Prospectus, amendment or supplement for review
and will not make, prepare, use, authorize, approve, refer to or file any such proposed amendment or supplement to which the Representatives reasonably object.
(d) Notice to the Representatives. The Company will advise the Representatives promptly, and confirm such advice in writing, (i) when any amendment to the Registration Statement has been filed
or becomes effective; (ii) when any supplement to the Prospectus or any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed; (iii) of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (iv) of the issuance by
the Commission of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Time of Sale Information or the Prospectus or the initiation or threatening of any
proceeding for that purpose or pursuant to Section 8A of the Securities Act; (v) of the occurrence of any event within the Prospectus Delivery Period as a result of which the Prospectus, the Time of Sale Information or any Issuer Free
Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances existing when the Prospectus, the Time of Sale Information or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; and (vi) of the receipt by the Company of any notice of objection of the Commission
to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of
the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of
the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Time of Sale Information or the Prospectus or suspending any such qualification of the Securities and, if any such order is issued, will use its
reasonable best efforts to obtain as soon as possible the withdrawal thereof.
(e) Ongoing Compliance. (1) If
during the Prospectus Delivery Period (i) any event shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material
Page 19
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading
or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will promptly notify the Representatives thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish
to the Underwriters such amendments or supplements to the Prospectus as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to
a purchaser, be misleading or so that the Prospectus will comply with law and (2) if at any time prior to the Closing Date (i) any event shall occur or condition shall exist as a result of which the Time of Sale Information as then amended
or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Time of Sale Information is delivered to
a purchaser, not misleading or (ii) it is necessary to amend or supplement the Time of Sale Information to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph
(c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Time of Sale Information as may be necessary so that
the statements in the Time of Sale Information as so amended or supplemented will not, in the light of the circumstances under which they were made, be misleading or so that the Time of Sale Information will comply with law.
(f) Blue Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such
jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for the distribution of the Securities; provided that the Company shall not be required to (i) qualify as a
foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject
itself to taxation in any such jurisdiction if it is not otherwise so subject.
(g) Earning Statement. The Company will
make generally available to its security holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder
covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective date” (as defined in Rule 158) of the Registration Statement.
(h) Clear Market. For a period of 75 days after the date of the Prospectus, the Company will not (i) offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a
registration statement under the Securities Act relating to, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to make any offer, sale, pledge,
disposition or filing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or any such other securities, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or
Page 20
otherwise, without the prior written consent of the Representatives. The foregoing sentence shall not in any event apply to: (A) the issuance of the Securities to be sold hereunder or the
Underlying Securities; (B) any of the transactions contemplated under the caption “Description of the convertible note hedge and warrant transactions” in the Time of Sale Information and the Prospectus; (C) the issuance of Rights
or the securities issuable upon exercise of the Rights, or the issuance of securities in exchange for the Rights pursuant to the Rights Agreement; (D) the issuance of shares of Common Stock upon the exercise of an option or warrant, the vesting
or settlement of any restricted stock units or other equity compensation awards or the conversion of a security in each case outstanding on the date hereof; (E) the grant of options, restricted stock units, rights to purchase or other equity
compensation awards, or the issuance of shares of Common Stock, in each case to employees, officers, directors, advisors or consultants of the Company pursuant to equity compensation and employee stock purchase plans existing on the date hereof and
described in the Prospectus, or hereafter assumed, or the issuance of any shares of Common Stock upon the exercise, vesting or settlement of such equity compensation awards; (F) the issuance of shares of Common Stock pursuant to that certain
Agreement and Plan of Merger, dated December 7, 2007 (the “Merger Agreement”), by and between the Company, Corazon Acquisition Inc., CardioSpectra, Inc. and Christopher E. Banas and Paul Castella (such shares the “Earn-Out
Shares”) or (G) the filing of any registration statement under the Securities Act (1) on Form S-8 in respect of any equity compensation plans or arrangements maintained or assumed by the Company or (2) that the Company may be
required to file pursuant to either (a) the Merger Agreement with respect to the Earn-Out Shares or (b) the Rights Agreement or under applicable law with respect to the Rights and the securities issuable upon exercise or exchange of the
Rights.
(i) Use of Proceeds. The Company will apply the net proceeds from the sale of the Securities as described in
the Registration Statement, the Time of Sale Information and the Prospectus under the heading “Use of proceeds”.
(j) No Stabilization. The Company will not take, directly or indirectly, any action designed to or that could reasonably be
expected to cause or result in any stabilization or manipulation of the price of the Securities and will not take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities contemplated hereby.
(k) Common Stock Reserve. The Company will reserve and keep available at all times, free of pre-emptive rights, shares
of Common Stock for the purpose of enabling the Company to satisfy all obligations to issue the Underlying Securities upon conversion of the Securities. The Company will use its reasonable efforts to cause the Underlying Securities to be listed on
the Nasdaq Global Select Market (the “Exchange”).
(l) Reports. So long as the Securities are outstanding,
the Company will furnish to the Representatives, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Securities generally, and copies of any reports and financial statements
furnished to or filed with the Commission or any national securities exchange or automatic quotation system; provided, however, that the Company shall not be required to furnish any such reports or other communications pursuant to this paragraph
that are filed with or furnished to the Commission and accessible through the EDGAR database.
Page 21
(m) Record Retention. The Company will, pursuant to reasonable procedures developed
in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.
5. Certain Agreements of the Underwriters. Each Underwriter hereby represents and agrees that:
(a) It has not and will not use, authorize use of, refer to, or participate in the planning for use of, any “free writing prospectus”, as defined in Rule 405 under the Securities Act (which term
includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that
contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing
Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show), or (iii) any free writing prospectus prepared by such
Underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i) or (iii), an “Underwriter Free Writing Prospectus”).
(b) It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final
terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; provided that Underwriters may use a term sheet substantially in the form of Annex B hereto without the consent of
the Company; provided further that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet.
(c) It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering (and
will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).
6.
Conditions of Underwriters’ Obligations. The obligation of each Underwriter to purchase the Underwritten Securities on the Closing Date or the Option Securities on the Additional Closing Date, as the case may be as provided herein is
subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:
(a) Registration Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose, pursuant to Rule 401(g)(2) or
pursuant to Section 8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the
case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to
the reasonable satisfaction of the Representatives.
Page 22
(b) Representations and Warranties. The representations and warranties of the Company
contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be (except to the extent expressly made as of an earlier date, in which case as of such earlier date);
and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be.
(c) No Downgrade. Subsequent to the earlier of (A) the Time of Sale and (B) the execution and delivery of this
Agreement, if there are any debt securities or preferred stock of, or guaranteed by, the Company or any of its subsidiaries that are rated by a “nationally recognized statistical rating organization,” as such term is defined by the
Commission for purposes of Rule 436(g)(2) under the Securities Act, (i) no downgrading shall have occurred in the rating accorded any such debt securities or preferred stock and (ii) no such organization shall have publicly announced that
it has under surveillance or review, or has changed its outlook with respect to, its rating of any such debt securities or preferred stock (other than an announcement with positive implications of a possible upgrading).
(d) No Material Adverse Change. No event or condition of a type described in Section 3(g) hereof shall have occurred or shall
exist, which event or condition is not described in the Time of Sale Information (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the reasonable judgment of
the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this
Agreement, the Time of Sale Information and the Prospectus.
(e) Officer’s Certificate. The Representatives shall
have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer of the Company or another senior executive officer of the Company who is satisfactory to the Representatives
(i) confirming that such officer has carefully reviewed the Registration Statement, the Time of Sale Information and the Prospectus and, to the best knowledge of such officer, the representations set forth in Sections 3(b) and 3(d) hereof are
true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed
or satisfied hereunder at or prior to such Closing Date and (iii) to the effect set forth in paragraphs (a), (c) and (d) above.
(f) Comfort Letters. On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, KPMG LLP and Ernst & Young LLP shall have each furnished to
the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and
information of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in the Registration
Statement, the Time of Sale Information and the Prospectus; provided, that the letter delivered by KPMG LLP on the Closing Date or the Additional Closing Date, as the case
Page 23
may be, shall use a “cut-off” date no more than three business days prior to such Closing Date or such Additional Closing Date, as the case may be.
(g) Opinion and 10b-5 Statement of Counsel for the Company. Cooley LLP, counsel for the Company, shall have furnished to the
Representatives, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in the forms attached as Exhibit B (with
appropriate modifications reasonably satisfactory to the Representatives for any opinion and 10b-5 statement delivered on any Additional Closing Date).
(h) Opinion of Anderson Mori & Tomotsune. Anderson Mori & Tomotsune, counsel for the Company in Japan, shall have furnished to the Representatives, at the request of the Company,
their opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, with respect to such matters as the Representatives may reasonably request.
(i) Opinion of Altius Lawyers. Altius Lawyers, counsel for the Company in Belgium, shall have furnished to the Representatives, at
the request of the Company, their opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, with respect to such matters as the Representatives may reasonably request.
(j) Opinion of Haynes and Boone, LLP. Haynes and Boone, LLP, intellectual property counsel for the Company, shall have furnished
to the Representatives, at the request of the Company, their opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, with respect to such matters as the Representatives may reasonably
request.
(k) Opinion and 10b-5 Statement of Counsel for the Underwriters. The Representatives shall have received on
and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and 10b-5 statement of Latham & Watkins LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request,
and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.
(l) Intellectual Property Certificate. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the Company’s
Director, Intellectual Property, in the form agreed on the date hereof.
(m) No Legal Impediment to Issuance. No action
shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as
the case may be, prevent the issuance or sale of the Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent
the issuance or sale of the Securities.
(n) Good Standing. The Representatives shall have received on or prior to the
Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the
Page 24
good standing of the Company, dated as of Closing Date or the Additional Closing Date, as the case may be, and its subsidiaries, dated as a date immediately prior to such Closing Date or
Additional Closing Date, in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may reasonably request, in each case in a form reasonably acceptable to the
Representatives and in each case only where the concept of good standing is recognized under the laws of the applicable jurisdiction.
(o) Exchange Listing. An application for the listing of the Underlying Securities shall have been submitted to the Exchange.
(p) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between you and
the executive officers and directors of the Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing
Date or Additional Closing Date, as the case may be.
(q) Additional Documents. On or prior to the Closing Date or the
Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.
All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with
the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.
7.
Indemnification and Contribution.
(a) Indemnification of the Underwriters. The Company agrees to indemnify and
hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any
and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or
several, that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement
thereto), any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) or any Time of Sale Information (including any Time of Sale Information that has subsequently been amended), or
caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case
except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any
Page 25
Underwriter consists of the information described as such in subsection (b) below.
(b) Indemnification of the Company. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration Statement
and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to
any losses, claims, damages or liabilities, that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus or any Time of Sale
Information, it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession figure appearing in the
third paragraph under the caption “Underwriting”, the information contained in the thirteenth, seventeenth and eighteenth paragraphs under the caption “Underwriting”, and the information contained in the first sentence of the
twenty-first paragraph with respect to the actions of the Underwriters under the caption “Underwriting”.
(c)
Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to
either paragraph (a) or (b) above, such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the
failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under paragraph (a) or (b) above except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights
or defenses) by such failure; and provided, further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph (a) or
(b) above. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified
Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person in such proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as
incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the
Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have
reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties)
include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interest between them. It is understood and agreed that the
Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition
Page 26
to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its
affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and
any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be
a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding
effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request, (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in
accordance with such request prior to the date of such settlement unless such Indemnifying Person has (a) reimbursed all undisputed amounts and only failed to reimburse amounts disputed in good faith and (b) provided detail regarding the
reasons for the failure to reimburse amounts requested by the Indemnified Person and (iii) such Indemnified Person shall have given the Indemnifying Person at least 30 days’ prior notice of its intention to settle. No Indemnifying Person
shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder
by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject
matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.
(d) Contribution. If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified
Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid
or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the
other, from the offering of the Securities or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant
equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the
Company from the sale of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering
price of the Securities. The relative fault of the Company, on the one hand, and the Underwriters, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
Page 27
omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission.
(e) Limitation on Liability. The Company and the
Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph
(d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of this
Section 7, in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities
exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this Section 7 are several in
proportion to their respective purchase obligations hereunder and not joint.
(f) Non-Exclusive Remedies. The remedies
provided for in this Section 7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.
8. Effectiveness of Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
9. Termination. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the
Company, if after the execution and delivery of this Agreement and prior to the Closing Date or, in the case of the Option Securities, prior to the Additional Closing Date (i) trading generally shall have been suspended or materially limited on
or by any of the New York Stock Exchange or the Nasdaq Global Select Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general
moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or
crisis, either within or outside the United States, that, in the reasonable judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the
Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Prospectus.
10. Defaulting Underwriter.
Page 28
(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any
Underwriter defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Securities by other persons
satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Securities, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Securities on such terms. If other persons become obligated or agree to purchase the Securities of a
defaulting Underwriter, either the non-defaulting Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of
counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the
Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term “Underwriters” includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in
Schedule 1 hereto that, pursuant to this Section 10, purchases Securities that a defaulting Underwriter agreed but failed to purchase.
(b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph
(a) above, the aggregate number of Securities that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be does not exceed one-eleventh of the aggregate number of Securities to be purchased on such date, then
the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of
Securities that such Underwriter agreed to purchase on such date) of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made.
(c) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the
non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Securities that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the
aggregate amount of Securities to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the
Underwriters to purchase Securities on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant to this Section 10 shall be
without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses to the extent set forth in Section 11 hereof and except that the provisions of Section 7 hereof shall not
terminate and shall remain in effect.
(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it
may have to the Company or any non-defaulting Underwriter for damages caused by its default.
11. Payment of
Expenses.
Page 29
(a) Whether or not the transactions contemplated by this Agreement are consummated or this
Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale,
preparation and delivery of the Securities and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer
Free Writing Prospectus, any Time of Sale Information and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the costs of reproducing and distributing each of the Transaction
Documents; (iv) the fees and expenses of the Company’s counsel and independent accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the
Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related reasonably-documented fees and expenses of counsel for the
Underwriters); (vi) any fees charged by rating agencies for rating the Securities; (vii) the fees and expenses of the Trustee and any paying agent (including related fees and expenses of any counsel to such parties); (viii) all
expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA (provided such expenses and application fees shall not exceed $5,000) and the approval of the Securities for book-entry transfer by
DTC; and (ix) all expenses incurred by the Company in connection with any “road show” presentation to potential investors; and (x) all expenses and application fees related to the listing of the Underlying Securities on the
Exchange. It is understood, however, that except as expressly provided in Section 7 and this Section 11, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel and transfer taxes
payable on resale of any of the Securities by them.
(b) If (i) this Agreement is validly terminated pursuant to clause
(ii) of Section 9 prior to the Closing Date, (ii) the Company for any reason (other than (x) for a termination pursuant to clauses (i), (iii) or (iv) of Section 9, (y) a termination pursuant to Section 10
or (z) as a result of the failure of the condition set forth in Section 6(k) to be satisfied) fails to tender the Underwritten Securities for delivery to the Underwriters or (iii) the Underwriters decline to purchase the Underwritten
Securities for any reason permitted under this Agreement (other than (x) for a termination pursuant to clauses (i), (iii) or (iv) of Section 9, (y) a termination pursuant to Section 10 or (z) as a result of the
failure of the condition set forth in Section 6(k) to be satisfied), the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the
Underwriters in connection with this Agreement and the offering contemplated hereby.
12. Persons Entitled to Benefit of
Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to in Section 7 hereof. Nothing in this
Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Underwriter shall be
deemed to be a successor merely by reason of such purchase.
Page 30
13. Survival. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery
of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters.
14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term
“affiliate” has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the
term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act.
15. Miscellaneous.
(a) Authority of the Representatives. Any action by the Underwriters hereunder may be taken by J.P. Morgan Securities
LLC and Goldman, Sachs & Co. on behalf of the Underwriters, and any such action taken by J.P. Morgan Securities LLC and Goldman, Sachs & Co. shall be binding upon the Underwriters.
(b) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358);
Attention: Equity Syndicate Desk and c/o Goldman, Sachs & Co., 200 West Street, New York, New York 10282, Attention: Registration Department. Notices to the Company shall be given to it at 3661 Valley Centre Drive, Suite 200, San Diego,
California 92130, (fax: (858) 720-0325); Attention: Senior Vice President and General Counsel, with a copy to Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121-1909 (fax: (858) 550-6420) Attention: Matthew Browne, Esq.
(c) Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement
shall be governed by and construed in accordance with the laws of the State of New York.
(d) Counterparts. This
Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument.
(e) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.
(f)
Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.
[SIGNATURE PAGE FOLLOWS]
Page 31
If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below.
|
|
|
| Very truly yours, |
|
| VOLCANO CORPORATION |
|
|
| By |
|
/s/ Darin Lippoldt |
|
|
Darin Lippoldt |
| Title: |
|
SVP & GC |
Accepted as of the date first
set forth above:
For itself and on behalf of the
several Underwriters listed
in Schedule 1
hereto.
|
|
|
| J.P. MORGAN SECURITIES LLC |
|
|
| By |
|
/s/ Jason Wood |
|
|
Authorized Signatory |
|
|
|
| GOLDMAN, SACHS & CO. |
|
|
| By |
|
/s/ Daniel M. Young |
|
|
Authorized Signatory |
|
|
Daniel M. Young |
|
|
Managing Director |
Schedule 1
|
|
|
|
|
| Underwriter |
|
|
|
Principal Amount |
| J.P. Morgan Securities LLC |
|
|
|
$300,000,000 |
| Goldman, Sachs & Co. |
|
|
|
$100,000,000 |
|
|
|
|
|
|
|
Total |
|
$400,000,000 |
Schedule 2
Axsun Technologies, Inc.
CardioSpectra, Inc.
Fluid Medical, Inc.
Sync-Rx Ltd.
Volcalypso, Inc.
Mormont Ltd.
Volcano Japan Co., Ltd.
Volcano Europe,
B.V.B.A.
Volcano Netherlands Holdings, B.V.
Volcano Therapeutics South Africa (Pty) Ltd.
Volcarica, Sociedad de Responsabilidad Limitada
Annex A
a. Time of Sale Information
Term sheet containing the terms of the
Securities, substantially in the form of Annex B.
Annex B
Filed pursuant to Rule 433 under the Securities Act of 1933
Issuer
Free Writing Prospectus dated December 4, 2012
Relating to Preliminary Prospectus Supplement dated December 3,
2012
Registration Statement No. 333-169341
PRICING TERM SHEET
Dated December 4, 2012 to the
Preliminary Prospectus Supplement Referred to
Below
Volcano Corporation
Offering of
$400,000,000 aggregate principal amount of
1.75% Convertible Senior Notes due 2017
The information in this pricing term sheet relates only to the offering of the Convertible Senior Notes and should be read together with (i) the preliminary prospectus supplement dated
December 3, 2012 relating to the offering of the Convertible Senior Notes, including the documents incorporated by reference therein (the “Preliminary Prospectus Supplement”), and (ii) the accompanying prospectus dated
September 13, 2010, each filed with the Securities and Exchange Commission (the “SEC”).
|
|
|
| Issuer: |
|
Volcano Corporation, a Delaware corporation |
|
|
| NASDAQ Global Select Market Symbol for the Issuer’s common stock common stock: |
|
VOLC |
|
|
| Trade date: |
|
December 5, 2012 |
|
|
| Expected settlement date: |
|
December 10, 2012 |
|
|
| Securities offered: |
|
1.75% Convertible Senior Notes due 2017 (the “Notes”) |
|
|
| Aggregate principal amount offered: |
|
$400,000,000 aggregate principal amount of Notes |
|
|
| Underwriters’ option to purchase additional Notes: |
|
Up to $60,000,000 aggregate principal amount of additional Notes |
|
|
| Maturity date: |
|
December 1, 2017, unless earlier repurchased or converted |
|
|
|
| Annual interest rate: |
|
1.75% per annum, accruing from the settlement date |
|
|
| Interest payment dates: |
|
Each June 1 and December 1, beginning on June 1, 2013 |
|
|
| Regular record dates: |
|
May 15 and November 15 |
|
|
| Public offering price: |
|
100% |
|
|
| Closing stock price: |
|
$25.06 per share of the Issuer’s common stock on The NASDAQ Global Select Market as of December 4, 2012 |
|
|
| Conversion premium: |
|
Approximately 31% above the closing stock price on December 4, 2012 |
|
|
| Initial Conversion price: |
|
Approximately $32.83 per share of the Issuer’s common stock, subject to adjustment |
|
|
| Initial Conversion rate: |
|
30.4612 shares of the Issuer’s common stock per $1,000 principal amount of the Notes, subject to adjustment |
|
|
| Joint book-running managers: |
|
J.P. Morgan Securities LLC
Goldman, Sachs & Co. |
|
|
| CUSIP number: |
|
928645AB6 |
|
|
| ISIN number: |
|
US928645AB67 |
|
|
| Use of proceeds: |
|
The Issuer expects that the proceeds from the offering will be approximately $387.1 million (or $445.3 million if the underwriters exercise their over-allotment option in full),
after deducting fees and estimated transaction expenses associated with the offering and the convertible note hedge transactions and the warrant transactions described below. The Issuer expect to use approximately $31.4 million of the net proceeds
from the offering to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds that the Issuer receives from the warrant transactions), and may use up to approximately $105.0 million of the net
proceeds from the offering to fund repurchases of up to $90 million of the Issuer’s outstanding 2.875% Convertible Senior Notes due 2015, or the 2015 notes, concurrently with the offering through individually negotiated transactions. The Issuer
may also use a |
|
|
|
|
|
portion of the net proceeds to invest in or acquire complementary products, businesses or technologies. Acquisitions are a key element
of the Issuer’s strategy and, at any given time, the Issuer may be in discussions with third parties regarding potential acquisitions. Currently there are potential acquisitions in various stages of discussion, but, except with respect to the
acquisition of Crux described under “Summary—Recent developments” in the Preliminary Prospectus Supplement, which the Issuer expects to close before the end of 2012, the Issuer does not have any definitive agreements relating to any
such acquisitions. The remaining net proceeds are intended for working capital and general corporate purposes. In connection with any repurchases of the Issuer’s outstanding 2015 notes, the Issuer expects to terminate the convertible note hedge transactions and warrant transactions the Issuer entered into
with JPMorgan Chase Bank, National Association, or JPMCB, at the time of the offering of the 2015 notes in an amount corresponding to the portion of the 2015 notes so repurchased. As a result of the partial termination of these transactions, the
Issuer expects to receive from JPMCB a net payment resulting from the amount payable by JPMCB to the Issuer with respect to the termination of the existing convertible note hedge transactions and the amount payable by the Issuer to JPMCB with
respect to the termination of the existing warrant transactions. The amount of such net payment will depend on many factors, including, without limitation, the market price of the Issuer’s common stock and overall market conditions at the time
these transactions are partially terminated. The Issuer has been advised by JPMCB that it or its affiliate does not expect to unwind its existing hedge positions with respect to these transactions and will instead use these existing hedge positions
in connection with establishing its initial hedge positions with respect to the convertible note hedge transactions and warrant transactions entered into in connection with the offering.
Pending these uses and potential uses, the Issuer intends to invest the net proceeds
from the offering primarily in investment-grade, interest bearing instruments. See “Use of proceeds” in the Preliminary Prospectus Supplement. |
|
|
|
| |
|
If the underwriters exercise their over-allotment option, the Issuer will use a portion of the
net proceeds from the sale of the additional Notes to pay the cost of entering into
additional
convertible note hedge transactions (after such cost is partially offset by the proceeds that
the Issuer would receive from the additional warrant transactions that the Issuer expects to
enter into at such time) and for general
corporate purposes. |
|
|
| Ranking |
|
The Notes will be the Issuer’s general unsecured obligations and will rank:
• senior in right of payment to all of the Issuer’s
existing and future unsecured indebtedness that is expressly subordinated in right of payment to the Notes;
• equal in right of payment with all of the Issuer’s
existing and future unsecured liabilities that are not so subordinated; • effectively subordinated to any of the Issuer’s secured indebtedness that the Issuer incurs to the extent of the value of the assets securing
such indebtedness; and
• structurally subordinated to all existing and future
liabilities incurred by the Issuer’s subsidiaries. As of September
30, 2012, the Issuer had indebtedness of $115.0 million (without giving effect to the equity component of convertible debt or any debt discount). As of September 30, 2012, the Issuer did not have a material amount of secured indebtedness, and the
Issuer’s subsidiaries had approximately $17.4 million of outstanding indebtedness, trade payables and other obligations (excluding intercompany liabilities). After giving effect to the issuance of the Notes (assuming no exercise of the
underwriters’ over-allotment option) and the use of proceeds therefrom (assuming no repurchase of the 2015 notes, and without giving effect to the equity component of the Notes or any debt discount), the Issuer’s total consolidated
indebtedness as of September 30, 2012 would have been $515.0 million. |
|
|
|
| Adjustment to shares delivered Upon conversion upon a make-whole fundamental change: |
|
The following table sets forth the number of additional shares by which the conversion rate will be increased for each $1,000 principal amount of Notes surrendered for conversion
in connection with a make-whole fundamental change having the stock price and effective date set forth below: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock price |
|
| Effective Date |
|
$25.06 |
|
|
$27.50 |
|
|
$30.00 |
|
|
$32.50 |
|
|
$35.00 |
|
|
$37.50 |
|
|
$40.00 |
|
|
$50.00 |
|
|
$60.00 |
|
|
$80.00 |
|
|
$100.00 |
|
| 12/10/2012 |
|
|
9.4430 |
|
|
|
7.3872 |
|
|
|
6.0111 |
|
|
|
4.9430 |
|
|
|
4.1032 |
|
|
|
3.4353 |
|
|
|
3.1303 |
|
|
|
1.7110 |
|
|
|
1.0057 |
|
|
|
0.3899 |
|
|
|
0.1532 |
|
| 12/1/2013 |
|
|
9.4430 |
|
|
|
7.3625 |
|
|
|
5.8933 |
|
|
|
4.7654 |
|
|
|
3.8896 |
|
|
|
3.2024 |
|
|
|
2.8755 |
|
|
|
1.4843 |
|
|
|
0.8322 |
|
|
|
0.3004 |
|
|
|
0.1097 |
|
| 12/1/2014 |
|
|
9.4430 |
|
|
|
7.2380 |
|
|
|
5.6582 |
|
|
|
4.4631 |
|
|
|
3.5512 |
|
|
|
2.8499 |
|
|
|
2.4883 |
|
|
|
1.1730 |
|
|
|
0.6118 |
|
|
|
0.2008 |
|
|
|
0.0667 |
|
| 12/1/2015 |
|
|
9.4430 |
|
|
|
6.9161 |
|
|
|
5.1991 |
|
|
|
3.9293 |
|
|
|
2.9880 |
|
|
|
2.2883 |
|
|
|
1.9114 |
|
|
|
0.7608 |
|
|
|
0.3505 |
|
|
|
0.1030 |
|
|
|
0.0301 |
|
| 12/1/2016 |
|
|
9.4430 |
|
|
|
6.3700 |
|
|
|
4.4164 |
|
|
|
3.0302 |
|
|
|
2.0635 |
|
|
|
1.3995 |
|
|
|
1.0388 |
|
|
|
0.2550 |
|
|
|
0.0907 |
|
|
|
0.0292 |
|
|
|
0.0075 |
|
| 12/1/2017 |
|
|
9.4430 |
|
|
|
5.9024 |
|
|
|
2.8721 |
|
|
|
0.3080 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
The exact stock prices and effective dates may not be set forth in the table above, in which case:
| |
• |
|
If the stock price is between two stock prices in the table or the effective date is between two effective dates in the table, the number of additional
shares will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock prices and the earlier and later effective dates, as applicable, based on a 365-day year.
|
| |
• |
|
If the stock price is greater than $100.00 (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table
above), no additional shares will be added to the conversion rate. |
| |
• |
|
If the stock price is less than $25.06 (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table
above), no additional shares will be added to the conversion rate. |
Notwithstanding the foregoing, in no
event will the conversion rate, as increased pursuant to this section by the number of additional shares, exceed 39.9042 shares of common stock per $1,000 principal amount of Notes, subject to adjustment in the same manner, at the same time and on
account of the same events for which the conversion rate is required to be adjusted as set forth in the Preliminary Prospectus Supplement under “Description of notes—Conversion rights—Conversion rate adjustments.”
Capitalization
The following table sets forth, on an unaudited basis, the Issuer’s capitalization as of September 30, 2012:
| |
• |
|
on an actual basis; and |
| |
• |
|
on an as adjusted basis to give effect to (1) the sale of the Notes (assuming the underwriters’ over-allotment option is not exercised),
after deducting the underwriters’ discount and estimated offering expenses payable by the Issuer; and (2) the application of the estimated net proceeds as set forth under “Use of Proceeds” in the Preliminary Prospectus Supplement
(assuming no repurchase of the 2015 notes or partial termination of the convertible note hedge transactions and warrant transactions entered into in connection therewith at the time of the offering of the 2015 notes). |
The following table does not give effect to the acquisition of Sync-Rx or the pending acquisition of Crux. You should read the following table in
conjunction with the Issuer’s consolidated financial statements and accompanying notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, each in the Issuer’s Annual Report
on Form 10-K for the year ended December 31, 2011 and in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, each of which is incorporated by reference in the Preliminary Prospectus
Supplement.
|
|
|
|
|
|
|
|
|
| |
|
As of September 30, 2012 |
|
| (In thousands, except par value amounts) |
|
Actual |
|
|
As Adjusted |
|
| Long-term debt, less current portion: |
|
|
|
|
|
|
|
|
| 1.75% Convertible Senior Notes due 2017(1) |
|
$ |
— |
|
|
$ |
312,581 |
|
| 2.875% Convertible Senior Notes due 2015(2) |
|
|
99,238 |
|
|
|
99,238 |
|
| Other long term debt (3) |
|
|
38 |
|
|
|
38 |
|
|
|
|
|
|
|
|
|
|
| Total long-term debt |
|
|
99,276 |
|
|
|
411,857 |
|
|
|
|
|
|
|
|
|
|
| Stockholders’ equity: |
|
|
|
|
|
|
|
|
| Preferred stock, par value of $0.001, 10,000 shares authorized; no shares issued and outstanding, actual and as
adjusted |
|
|
— |
|
|
|
— |
|
| Common stock, par value of $0.001, 250,000 shares authorized; 53,835 shares issued and outstanding, actual and as adjusted
(4) |
|
|
54 |
|
|
|
54 |
|
| Additional paid-in capital(1) |
|
|
454,269 |
|
|
|
498,245 |
|
| Accumulated other comprehensive loss |
|
|
(747 |
) |
|
|
(747 |
) |
| Accumulated deficit |
|
|
(84,379 |
) |
|
|
(84,379 |
) |
|
|
|
|
|
|
|
|
|
| Total stockholders’ equity |
|
|
369,197 |
|
|
|
413,173 |
|
|
|
|
|
|
|
|
|
|
| Total capitalization |
|
$ |
468,473 |
|
|
$ |
825,030 |
|
|
|
|
|
|
|
|
|
|
| (1) |
Amounts shown reflect the application of ASC 470-20, which requires issuers to separately account for the debt and equity components of certain types of convertible
debt instruments. In accordance with ASC 470-20, the Issuer estimates that $400.0 million of the aggregate principal amount of the Notes will be recognized (and, to the extent applicable, reflected in the table above) as follows (in thousands):
|
|
|
|
|
|
|
|
| Equity component |
|
|
|
$ |
75,244 |
|
|
|
|
|
|
|
|
| Liability component: |
|
|
|
|
|
|
| Principal |
|
|
|
$ |
322,248 |
|
| Less: debt discount |
|
|
|
|
(9,667 |
) |
|
|
|
|
|
|
|
| Net carrying amount |
|
|
|
$ |
312,581 |
|
|
|
|
|
|
|
|
| (2) |
Amounts shown reflect the application of ASC 470-20 with respect to the 2015 notes. The amount of 2015 notes will decrease to the extent the Issuer is able to
repurchase the 2015 notes. See “Use of Proceeds” in the Preliminary Prospectus Supplement. |
| (3) |
Other long-term debt is composed entirely of the Issuer’s capital lease obligations. |
| (4) |
The common stock shown as issued and outstanding in the table above is based on 53,835,423 shares of common stock outstanding as of September 30, 2012 and excludes
any shares of common stock reserved for issuance upon conversion of the Notes and any shares of common stock reserved for issuance under the warrant transaction, and also excludes, as of September 30, 2012: (i) 3,746,199 shares of common
stock issuable upon the exercise of outstanding stock options, having a weighted average exercise price of $17.6683 per share; (ii) 931,621 shares of common stock issuable upon the vesting of outstanding restricted stock units; (iii) an
aggregate of up to 3,329,452 shares of common stock reserved for future issuance under the Issuer’s equity incentive and employee stock purchase plans and (iv) shares issuable upon conversion of the Issuer’s outstanding 2015 notes and
shares issuable upon exercise of the warrants issued in connection with the 2015 notes. As of September 30, 2012, the market price of the Issuer’s common stock did not exceed the conversion price of the 2015 notes or the strike price of
the related warrants, so no shares of stock were issuable as of such date upon conversion of the 2015 notes or exercise of the related warrants. |
The Issuer has filed a registration statement (including the Preliminary Prospectus Supplement and an accompanying prospectus dated December 3, 2012) with the SEC for the offering to which this
communication relates. Before you invest, you should read the Preliminary Prospectus Supplement, the accompanying prospectus and the other documents the Issuer has filed with the SEC for more complete information about the Issuer and the offering.
You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, copies may be obtained from J.P. Morgan Securities LLC at J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions at 1155 Long
Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204 or from Goldman, Sachs & Co. at from Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at 212-902-1171, fax at
212-902-9316 or email at prospectus-ny@ny.email.gs.com.
Exhibit A
FORM OF LOCK-UP AGREEMENT
November , 2012
J.P. MORGAN SECURITIES LLC
As Representative
of the
several Underwriters listed in
Schedule 1 to the Underwriting Agreement
c/o
J.P. Morgan Securities LLC
383 Madison Avenue
New York, NY 10179
|
|
|
| Re: |
|
Volcano Corporation — Public Offering |
Ladies and
Gentlemen:
The undersigned understands that you, as Representative of the Underwriters (as defined below), propose to enter
into an Underwriting Agreement (the “Underwriting Agreement”) with Volcano Corporation, a Delaware corporation (the “Company”), providing for the purchase and resale (the “Public Offering”) by the Underwriters named in
Schedule 1 to the Underwriting Agreement (whether one or several, the “Underwriters”), of Convertible Senior Notes due 2017 of the Company (the “Securities”). Capitalized terms used herein and not otherwise defined shall have the
meanings set forth in the Underwriting Agreement.
In consideration of the Underwriters’ agreement to purchase and make
the Public Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan Securities LLC on behalf of the
Underwriters, the undersigned will not, during the period ending 75 days after the date of the prospectus supplement relating to the Public Offering, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, $0.001 per share par value, of the Company (the “Common Stock”) or any
securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and
regulations of the Securities and Exchange Commission and securities which may be, or are, issued upon exercise of a stock option or warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition, (2) enter into any
swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by
delivery of Common Stock or such other securities, in cash or otherwise or (3) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common
Stock. Notwithstanding the foregoing, the foregoing restrictions shall not in any event apply to any sales, transfers or other dispositions of Common Stock or any securities convertible into or
exercisable for shares of Common Stock: (A) as a bona fide gift or gifts; (B) by will or intestate succession or to any trust the beneficiaries of which are exclusively the undersigned and/or a member or members of the immediate
family of the undersigned; (C) from or by a grantor retained annuity trust which exists as of the date hereof and was established for the direct or indirect benefit of the undersigned and/or any member of the immediate family of the undersigned
pursuant to the terms of such trust; (D) pursuant to a written trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which exists as of the date hereof; (E) to the Company in
connection with the “net” exercise of outstanding options to purchase Common Stock in accordance with the terms of such options; (F) to the Company or in sell-to-cover transactions in full or partial payment of taxes or tax
withholding obligations required to be paid or satisfied upon the settlement, vesting or exercise of any equity award granted by the Company; provided that in the case of any transfer or distribution pursuant to clause (A) (other than in
the case of charitable gifts to not-for-profit organizations) or (B), each donee, transferee or distributee shall execute and deliver to J.P. Morgan Securities LLC a lock-up letter in the form of this Letter Agreement; and provided further,
that in the case of any transfer or distribution pursuant to clause (A) or (B), such transfer is not a transfer for value and no filing by any party (donor, donee, transferor or transferee) under the Exchange Act or other public announcement
shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the 75-day restricted period referred to above). In addition, notwithstanding the
restrictions described herein, the undersigned may at any time after the date hereof enter into a written trading plan (a “New Plan”) meeting the requirements of Rule 10b5-1 of the Exchange Act relating to the sale of shares of Common
Stock or any securities convertible into or exercisable or exchangeable for Common Stock, provided that the securities subject to such New Plan may not be sold during the 75-day restricted period and no filing by the undersigned or the
Company under the Exchange Act, or other public announcement, shall be required or shall be made voluntarily in connection with the adoption of the New Plan.
In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any
transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.
The undersigned
hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the
successors, assigns, heirs or personal representatives of the undersigned.
It is understood that, if (A) the Company
notifies the Representative that it does not intend to proceed with the Public Offering, (B) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and
delivery of the Securities to be sold thereunder, or (C) the Public Offering shall not have been completed by December 31, 2012, this Letter Agreement shall immediately be terminated and the undersigned shall be released form all
obligations under this Letter Agreement. The
undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement.
[SIGNATURE PAGE FOLLOWS]
This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.
|
|
|
| Very truly yours, |
|
| [NAME OF OFFICER/DIRECTOR] |
|
|
| By: |
|
|
|
|
Name: |
|
|
Title: |
Exhibit B
OPINION AND 10B-5 STATEMENT OF COOLEY LLP
